Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTSGC-A24
- Development stage
- Phase 2
- Lead developer
- Oncotherapy Science
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
OTSGC-A24 is a peptide-based cancer vaccine developed for the treatment of advanced gastric cancer, specifically in patients with the HLA-A*24:02 haplotype. It is a cocktail of peptides that target five tumor-specific antigens—FOXM1, DEPDC1, KIF20A, URLC10, and VEGFR1. The vaccine works by inducing cytotoxic T lymphocyte (CTL) responses against these antigens presented on tumor cells, thereby promoting immune-mediated tumor cell killing. Preclinical studies demonstrated that both siRNA-mediated downregulation and active vaccination targeting these molecules led to tumor regression. Clinical trials have shown that OTSGC-A24 is well tolerated and capable of inducing significant CTL responses in patients[1][4][5]. The drug is administered subcutaneously at a recommended dose of 1 mg per injection[5]. Development has included combination studies with other immunotherapeutic agents such as nivolumab and ipilimumab[6].
- Other names
- Peptide vaccine (gastric cancer)
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)HLA-A*24 (Major histocompatibility complex class I molecule presenting MAGE-A4 peptide)Forkhead box protein M1-derived peptide epitopesKIF20A (Kinesin family member 20A)DEPDC1 (DEP domain-containing protein 1)pMHC-I (Peptide–MHC class I complex)LY6K (Lymphocyte antigen 6 complex locus protein K)
Beyond the preview
Go deeper on OTSGC-A24.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTSGC-A24.